MGI Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MGI's estimated annual revenue is currently $79.2M per year.(i)
  • MGI's estimated revenue per employee is $155,000

Employee Data

  • MGI has 511 Employees.(i)
  • MGI grew their employee count by 34% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4280M11139-4%$28M$63.3B
#2
$459.4M13737%N/AN/A
Add Company

What Is MGI?

MGI is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI produces sequencing instruments, reagents, equipment and related products to support life science research, agriculture, medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include sequencing, mass spectrometry, medical imaging and laboratory automation. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.

keywords:N/A

N/A

Total Funding

511

Number of Employees

$79.2M

Revenue (est)

34%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MGI News

2022-04-19 - Will Moneygram International Inc (MGI) Stay at the Top of the Financial Services Sector?

Will Moneygram International Inc (MGI) Stay at the Top of the Financial Services Sector? Friday, April 22, 2022 01:53 PM | InvestorsObserver Analysts.

2022-04-19 - MoneyGram Responds to Baseless Litigation and Claims by ...

(NASDAQ: MGI), a global leader in the evolution of digital P2P payments, responded to the meritless civil lawsuit filed by the Consumer...

2022-04-17 - MGI Tech, Nalagenetics Partner for Pharmacogenomics in ...

This article has been updated from a previous version to reflect clarifications made by MGI Tech about the nature of the partnership.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$186.3M5147%N/A
#2
$102.8M5145%N/A
#3
$158M5207%N/A
#4
$94.4M5217%N/A
#5
$95.3M536-4%$356.2M